Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

6-Hydroxybuspirone is a major active metabolite of buspirone: assessment of pharmacokinetics and 5-hydroxytryptamine1A receptor occupancy in rats.

Wong H, Dockens RC, Pajor L, Yeola S, Grace JE Jr, Stark AD, Taub RA, Yocca FD, Zaczek RC, Li YW.

Drug Metab Dispos. 2007 Aug;35(8):1387-92. Epub 2007 May 9.

PMID:
17494642
2.

Interaction of the novel antipsychotic aripiprazole with 5-HT1A and 5-HT 2A receptors: functional receptor-binding and in vivo electrophysiological studies.

Stark AD, Jordan S, Allers KA, Bertekap RL, Chen R, Mistry Kannan T, Molski TF, Yocca FD, Sharp T, Kikuchi T, Burris KD.

Psychopharmacology (Berl). 2007 Feb;190(3):373-82. Epub 2006 Nov 25.

PMID:
17242925
3.

The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.

Aihara K, Shimada J, Miwa T, Tottori K, Burris KD, Yocca FD, Horie M, Kikuchi T.

Brain Res. 2004 Apr 2;1003(1-2):9-17.

PMID:
15019558
4.

Indanyl piperazines as melatonergic MT2 selective agents.

Mattson RJ, Catt JD, Keavy D, Sloan CP, Epperson J, Gao Q, Hodges DB, Iben L, Mahle CD, Ryan E, Yocca FD.

Bioorg Med Chem Lett. 2003 Mar 24;13(6):1199-202.

PMID:
12643943
5.

Development of a presynaptic 5-HT1A antagonist.

Mattson RJ, Catt JD, Sloan CP, Gao Q, Carter RB, Gentile A, Mahle CD, Matos FF, McGovern R, VanderMaelen CP, Yocca FD.

Bioorg Med Chem Lett. 2003 Jan 20;13(2):285-8.

PMID:
12482441
6.

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors.

Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, Yocca FD, Molinoff PB.

J Pharmacol Exp Ther. 2002 Jul;302(1):381-9.

PMID:
12065741
7.
8.

BMS-181885, a 5-HT1B/1D receptor ligand, in experimental models predictive of antimigraine activity and coronary side-effect potential.

Saxena PR, De Vries P, Heiligers JP, Bax WA, Maassen VanDenBrink A, Yocca FD.

Eur J Pharmacol. 1998 Jun 26;351(3):329-39.

PMID:
9721025
9.
10.

Effects of avitriptan, a new 5-HT 1B/1D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential.

Saxena PR, De Vries P, Wang W, Heiligers JP, Maassen vandenBrink A, Bax WA, Yocca FD.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Feb;355(2):295-302.

PMID:
9050026
11.

5-HT1A receptor agonist effects of BMY-14802 on serotonin release in dorsal raphe and hippocampus.

Matos FF, Korpinen C, Yocca FD.

Eur J Pharmacol. 1996 Dec 12;317(1):49-54.

PMID:
8982718
12.

Lack of 5-hydroxytryptamine1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats.

Clarke WP, Yocca FD, Maayani S.

J Pharmacol Exp Ther. 1996 Jun;277(3):1259-66.

PMID:
8667186
13.
14.

Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.

Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD.

J Clin Psychiatry. 1995;56 Suppl 6:3-11. Review.

PMID:
7649970
15.
16.

Characterization of human 5-HT1 receptors expressed in Sf9 insect cells.

Parker EM, Grisel DA, Iben LG, Nowak HP, Mahle CD, Yocca FD, Gaughan GT.

Eur J Pharmacol. 1994 Jun 15;268(1):43-53.

PMID:
7925611
17.

Cloning and characterization of the rat 5-HT5B receptor. Evidence that the 5-HT5B receptor couples to a G protein in mammalian cell membranes.

Wisden W, Parker EM, Mahle CD, Grisel DA, Nowak HP, Yocca FD, Felder CC, Seeburg PH, Voigt MM.

FEBS Lett. 1993 Oct 25;333(1-2):25-31.

18.

[3H]-5-carboxamidotryptamine labels 5-HT1D binding sites in bovine substantia nigra.

Nowak HP, Mahle CD, Yocca FD.

Br J Pharmacol. 1993 Aug;109(4):1206-11.

19.
20.

A role for sigma binding in the antipsychotic profile of BMY 14802?

Taylor DP, Eison MS, Moon SL, Schlemmer RF Jr, Shukla UA, VanderMaelen CP, Yocca FD, Gallant DJ, Behling SH, Boissard CG, et al.

NIDA Res Monogr. 1993;133:125-57. Review.

PMID:
8232511
21.

Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.

Yevich JP, New JS, Lobeck WG, Dextraze P, Bernstein E, Taylor DP, Yocca FD, Eison MS, Temple DL Jr.

J Med Chem. 1992 Nov 27;35(24):4516-25.

PMID:
1361578
24.

[3H]5-carboxamidotryptamine labels multiple high affinity 5-HT1D-like sites in guinea pig brain.

Mahle CD, Nowak HP, Mattson RJ, Hurt SD, Yocca FD.

Eur J Pharmacol. 1991 Dec 3;205(3):323-4. No abstract available.

PMID:
1817966
25.
26.

Unique modulation of central 5-HT2 receptor binding sites and 5-HT2 receptor-mediated behavior by continuous gepirone treatment.

Yocca FD, Eison AS, Hyslop DK, Ryan E, Taylor DP, Gianutsos G.

Life Sci. 1991;49(24):1777-85.

PMID:
1682780
27.
28.
29.

Nefazodone: preclinical pharmacology of a new antidepressant.

Eison AS, Eison MS, Torrente JR, Wright RN, Yocca FD.

Psychopharmacol Bull. 1990;26(3):311-5. Review.

PMID:
2274630
30.

8-OH-DPAT and buspirone analogs inhibit the ketanserin-sensitive quipazine-induced head shake response in rats.

Yocca FD, Wright RN, Margraf RR, Eison AS.

Pharmacol Biochem Behav. 1990 Jan;35(1):251-4.

PMID:
2138331
31.

5-HT receptors linked to adenylyl cyclase activity in mammalian brain.

Yocca FD, Maayani S.

Ann N Y Acad Sci. 1990;600:212-23. Review. No abstract available.

PMID:
2123617
32.

Gepirone hydrochloride: preclinical pharmacology and recent clinical findings.

Yevich JP, Eison MS, Eison AS, Taylor DP, Yocca FD, VanderMaelen CP, Riblet LA, Robinson DS, Roberts DL, Temple DL.

Prog Clin Biol Res. 1990;361:443-51. Review. No abstract available.

PMID:
1981261
33.

Novel anxiolytic agents: actions on specific subtypes of central 5-HT receptors.

Yocca FD.

Prog Clin Biol Res. 1990;361:145-77. Review. No abstract available.

PMID:
1981257
35.
36.

BMY 7378, a buspirone analog with high affinity, selectivity and low intrinsic activity at the 5-HT1A receptor in rat and guinea pig hippocampal membranes.

Yocca FD, Hyslop DK, Smith DW, Maayani S.

Eur J Pharmacol. 1987 Jun 4;137(2-3):293-4. No abstract available.

PMID:
2886356
37.

Reduction in cortical 5HT2 receptor sensitivity after continuous gepirone treatment.

Eison AS, Yocca FD.

Eur J Pharmacol. 1985 May 20;111(3):389-92.

PMID:
2862051
38.

Effect of immobilization stress on rat pineal beta-adrenergic receptor-mediated function.

Yocca FD, Friedman E.

J Neurochem. 1984 May;42(5):1427-32.

PMID:
6142925
39.

Antidepressant drugs with varying pharmacological profiles alter rat pineal beta adrenergic-mediated function.

Friedman E, Yocca FD, Cooper TB.

J Pharmacol Exp Ther. 1984 Mar;228(3):545-50.

PMID:
6323672
40.

Effect of chronic lithium treatment on rat pineal rhythms: N-acetyltransferase, N-acetylserotonin and melatonin.

Yocca FD, de Paul Lynch V, Friedman E.

J Pharmacol Exp Ther. 1983 Sep;226(3):733-7.

PMID:
6193266
41.

The effect of chronic lithium treatment on rat pineal N-acetyltransferase rhythm.

Friedman E, Yocca FD.

J Pharmacol Exp Ther. 1981 Oct;219(1):121-4.

PMID:
6270296

Supplemental Content

Loading ...
Support Center